CERS

Cerus Corporation
NASDAQHEALTHCAREMEDICAL DEVICES

Key Statistics

Market Cap
$629.16M
P/E Ratio
EPS
$-0.05
Beta
1.77
52W High
$3.47
52W Low
$1.15
50-Day MA
$2.66
200-Day MA
$2.11
Dividend Yield
Profit Margin
-4.41%
Forward P/E
PEG Ratio
0.00

About Cerus Corporation

Cerus Corporation, a biomedical products company, is focused on developing and commercializing the INTERCEPT Blood System to improve blood safety. The company is headquartered in Concord, California.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$216.56M
Gross Profit (TTM)$114.76M
EBITDA$-1.62M
Operating Margin-0.66%
Return on Equity-15.40%
Return on Assets-0.93%
Revenue/Share (TTM)$1.13
Book Value$0.34
Price-to-Book9.40
Price-to-Sales (TTM)2.90
EV/Revenue3.011
EV/EBITDA1372.85
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)24.10%
Shares Outstanding$200.37M
Float$182.93M
% Insiders3.40%
% Institutions74.27%

Historical Volatility

HV 10-Day
53.99%
HV 20-Day
49.97%
HV 30-Day
55.99%
HV 60-Day
81.44%
HV Rank
16.3%

Volatility is currently contracting

Analyst Ratings

Consensus ($4.67 target)
3
Buy

Latest News

Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected to attend the ISBT Congress. “We look forward to highlighting how blood centers around the world are l.

Business Wire6/17/2026Neutral
Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena

HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, a significant shareholder of Cerus Corporation (NASDAQ: CERS) (“Cerus” or the “Company”), today announced his intention to withhold support for the Company's two director nominees at the upcoming 2026 annual meeting in the below open letter to shareholders. *** May 27, 2026 Fellow Shareholders, I am an individual shareholder in Cerus managing my own capital. In light of the Company's negative returns and failure to achieve profitability over the past.

Business Wire5/27/2026Neutral
Cerus Corporation Announces First Quarter 2026 Financial Results

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the first quarter ended March 31, 2026, and provided a business update. “We delivered a strong start to 2026, with first quarter performance driven by strength across our business, in particular by increasing demand for our INTERCEPT Fibrinogen Complex,” said William “Obi” Greenman, Cerus' president and chief executive officer. “As a result, we are raising our product revenue guidance for th.

Business Wire4/30/2026Neutral
Cerus Corporation Announces New, Four-Year Supply Agreement with French Blood Establishment for INTERCEPT Blood System

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the signing of a new, four-year supply agreement with Établissement Français du Sang (EFS), the French Blood Establishment, for the INTERCEPT Blood System. The agreement covers the INTERCEPT Blood System for platelets and plasma as well as the next generation, LED-based INT200 illumination device. “We are proud to announce a new four-year supply agreement with the French Blood Establishment,” said Christian Boute.

Business Wire4/27/2026Neutral
Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its first quarter 2026 financial results will be released on Thursday, April 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the.

Business Wire4/16/2026Neutral

More HEALTHCARE Stocks

Data last updated: 7/9/2026